GLMDGalmed Pharmaceuticals Ltd.
This is the year GLMD has to prove it’s not just a stock with a nice ticker symbol and a few clinical trials in the pipeline. The next catalyst — the Q2 2026 earnings release on October 6 — is the first real test, with an anchor of $4.54, a bull target of $6.50, and a bear fallback of $3.50. The market is leaning 50% toward the bull path, but the path is littered with potential twists: a strategic transaction on October 15, a Q3 earnings report on November 14, and a Q4 earnings release on February 14, 2027, all with their own bull and bear targets. The company’s fate hinges on whether it can deliver on its pipeline, secure partnerships, and show that it’s not just surviving but thriving in a sector that’s more competitive than ever.
The schedule
- Tue6Oct
Earnings release for Q2 2026, with potential guidance on pipeline progress and revenue outlook.
- Thu15Oct
Potential announcement of a strategic transaction or partnership, which could impact valuation and investor sentiment.
- Sat14Nov
Earnings release for Q3 2026, with potential updates on clinical trials and revenue performance.
- Sun14Feb
Earnings release for Q4 2026, with potential updates on drug development progress and financial results.
- Sun28Feb
Potential compliance milestone or regulatory update that could impact listing status or operations.
- Sat15May
Earnings release for Q1 2027, with potential updates on financial performance and strategic initiatives.
Past
- Sat15Aug
Actual outcome: Bull
Potential equity financing to extend cash runway outcome: bear (price reached our bear floor).
Given Galmed’s recurring operating losses and limited cash balance, the market will be watching closely for a potential equity raise or similar financing transaction around the back half of 2026. Any announced offering near a $0.95 share price would likely come at a discount and could materially change the share count and enterprise value.
